🧪 TrialInsufficient
Registered Phase 4 interventional trial (not yet recruiting). This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-termina
ClinicalTrials.gov · Jun 2026View trial ↗ Animal only
This mouse study investigated the molecular mechanisms by which tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist, affects the liver in metabolic dysfunction-associated steatotic liver disease (MASLD). Male C57BL/6J mice (n=32) were fed a high-fat, high-fructose (HFHFr) diet to induce MASLD and then randomized to receive no treatment, semaglutide (Sema), or TZP. Researchers combined RNA sequencing and liquid chromatography-mass spectrometry (LC-MS) to generate hepatic transcriptomic and proteomic profiles, with key targets validated by PCR and immunoblotting. The study found that HFHFr feeding produced hyperglycemia, insulin resistance, elevated liver enzymes, and hepatic steatosis and inflammation. Both TZP and Sema were associated with improvements in these parameters; TZP was associated with reductions in pro-inflammatory markers (MCP-1, IL-1β, TNF-α, GSDMD) and partial restoration of IL-10. Integrated omics analysis implicated the CCL2/CCR2 chemokine axis and PI3K-AKT signaling pathway as key molecular signatures associated with TZP's hepatic effects. Key limitations include the exclusive use of an animal model, a small sample size, and the mechanistic (non-causal) nature of omics associations.
BMC gastroenterology · Jun 2026DOI ↗ Review
This narrative review examines the continued clinical relevance of dulaglutide, a once-weekly GLP-1 receptor agonist, in the treatment of type 2 diabetes (T2D) amid growing adoption of newer incretin-based therapies such as semaglutide and tirzepatide. The authors synthesize evidence from major cardiovascular outcome trials, including the REWIND trial—which they highlight as the only GLP-1 receptor agonist trial to demonstrate a statistically significant reduction in major adverse cardiovascular events (MACE) in a predominantly primary prevention population over more than five years—and the SURPASS-CVOT, which established tirzepatide's non-inferiority to dulaglutide for cardiovascular outcomes. The review acknowledges that semaglutide and tirzepatide show superior HbA1c reduction and weight loss compared to dulaglutide, but argues that dulaglutide's fixed-dose, no-titration regimen, established cardiovascular safety profile, real-world tolerability, and lower cost support its continued use—particularly in low- and middle-income countries. Limitations include the narrative (non-systematic) review design, which is susceptible to selection bias, and the lack of head-to-head cardiovascular outcome trials directly comparing dulaglutide to semaglutide or tirzepatide.
Diabetology international · Jun 2026DOI ↗ Review
This review paper examines MOTS-c, a mitochondrial-derived microprotein (mitokine) encoded within the 12S rRNA gene, and its potential role in inflammatory lung diseases. The authors synthesize available experimental and clinical literature to explore how MOTS-c influences metabolic homeostasis, oxidative stress, inflammation, autophagy, cell death pathways (including apoptosis, ferroptosis, and pyroptosis), mitochondrial dysfunction, and immune responses. Key findings reported across the reviewed studies include: reduced circulating MOTS-c levels in various forms of acute respiratory distress; attenuation of lung injury following exogenous MOTS-c administration in preclinical models; a partial mechanistic link between remote ischemic preconditioning and MOTS-c release; decreased MOTS-c concentrations in chronic conditions such as COPD, obstructive sleep apnea, and asthma; and preliminary observations of elevated MOTS-c in lung cancer, tentatively attributed to NRF2-mediated antioxidant responses. The authors conclude that MOTS-c holds promise as both a biomarker and therapeutic candidate in respiratory medicine, while acknowledging that current evidence is largely preclinical and that well-designed translational and multicenter clinical trials are needed to confirm any clinical utility. Limitations include the heterogeneity of reviewed study designs and the early-stage, preliminary nature of much of the evidence.
Journal of translational medicine · Jun 2026DOI ↗ Limited · human
This post hoc analysis of the RECAP study examined how combination therapy with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and a glucagon-like peptide-1 receptor agonist (GLP-1RA) affected blood pressure (BP) control in Japanese patients with type 2 diabetes (T2D) and hypertension. Of 643 T2D patients in the original study, 431 with baseline hypertension were analyzed. Patients were grouped by which drug class was initiated first (GLP-1RA-preceding, n=207; SGLT2i-preceding, n=224). The study found that the rate of achieving the target office BP of less than 130/80 mmHg increased significantly from 25.4% after single-agent therapy to 33.3% after combination therapy was established. Office BP declined from 141.8/82.4 mmHg at baseline to 131.7/79.4 mmHg following combination therapy, and home systolic BP also decreased significantly. Propensity score-based inverse probability weighting analysis revealed no significant difference in BP outcomes based on which drug class was initiated first. Key limitations include the post hoc, non-randomized design, the single-ethnicity Japanese population, and potential residual confounding despite statistical adjustment.
Hypertension research : official journal of the Japanese Society of Hypertension · Jun 2026DOI ↗ InsufficientPreprint
This paper presents a theoretical hypothesis arguing that current GLP-1 and dual GIP/GLP-1 receptor agonist therapies (e.g., semaglutide, tirzepatide) produce weight loss plateaus because they only address one side of what the authors term the "mass balance equation" — net mass inflow (NMI) — while net mass outflow (NMO) passively and actively declines over time. The authors propose a "mass balance model" (MBM) as an alternative explanatory framework to the conventional energy balance model, framing the plateau as a predictable physical consequence rather than a vague compensatory metabolic adaptation. Based on this framework, the authors hypothesize that combining an NMI-reducing agent with an NMO-stabilizing or NMO-enhancing agent could produce greater, more durable weight loss and improved body composition. Candidate NMO-targeting agents discussed include SGLT2 inhibitors, activin/myostatin pathway inhibitors, and mitochondrial uncouplers. The paper is entirely theoretical; no original experimental data, clinical trials, or systematic evidence synthesis are presented. Its primary limitation is that the MBM framework and the dual-action hypothesis remain untested in human or animal studies.
Unknown journal · Jun 2026DOI ↗ Limited · human
This case report describes the use of tirzepatide — a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — in a 31-year-old woman diagnosed with Smith-Magenis syndrome (SMS), a rare neurodevelopmental disorder associated with intellectual disability, behavioral dysregulation, and hyperphagia-driven obesity. The patient had a lifelong history of obesity and aggressive behaviors that had not responded adequately to standard management. Following initiation and titration of tirzepatide, the authors report that the patient achieved approximately 9.4% body weight loss (~7.3 kg) over 10 months, along with improvements in fasting glucose levels. Caregivers also noted behavioral benefits, including reduced food-seeking behavior and impulsivity, and quantitative analysis reportedly showed a significant reduction in aggression. The treatment was described as well tolerated. The authors hypothesize that tirzepatide may engage both metabolic and central nervous system pathways relevant to the SMS phenotype. Key limitations include the single-patient design, the absence of a control condition, and the inherent difficulty in attributing behavioral improvements to tirzepatide alone in a complex neurodevelopmental disorder.
JCEM case reports · Jun 2026DOI ↗ Animal only
This study investigated whether MOTS-c, a small peptide encoded within mitochondrial DNA, could protect the heart from ischemia-reperfusion (IR) injury. Using the Langendorff isolated heart perfusion model in female Wistar rats (n=6 per group), researchers subjected hearts to 30 minutes of global ischemia followed by 60 minutes of reperfusion. MOTS-c was administered either before ischemia or at the start of reperfusion. The study evaluated cardiac mechanical function, oxidative stress, mitochondrial enzyme activities, membrane potential, mitochondrial DNA (mtDNA) copy number, and regulatory gene expression across two distinct mitochondrial subpopulations — subsarcolemmal and interfibrillar mitochondria. IR injury significantly impaired cardiac recovery, increased oxidative stress, reduced electron transport chain activity, and decreased mtDNA copy number and regulatory gene expression. MOTS-c treatment was associated with improved post-ischemic mechanical recovery, reduced oxidative stress, partial preservation of mitochondrial enzyme activity and membrane potential, and attenuation of mtDNA loss. Protective effects were seen in both mitochondrial subpopulations, though the magnitude varied. Key limitations include the exclusive use of an isolated ex vivo animal model, small group sizes, a single sex, and uncharacterized signaling mechanisms underlying the observed effects.
Molecular biology reports · Jun 2026DOI ↗ Animal only
This study investigated whether the mitochondrial-derived peptide MOTS-c could improve survival of ischemic tissue flaps used in reconstructive surgery — a context where distal necrosis due to poor blood flow remains a significant clinical challenge. Using a rat ischemic flap model, researchers employed a broad range of techniques including RNA sequencing, tissue clearing, laser speckle contrast imaging, laser Doppler blood flow analysis, histological staining, Western blotting, ELISA, immunofluorescence, and adeno-associated virus (AAV)-mediated gene overexpression. The study also used human umbilical vein endothelial cells (HUVECs) for in vitro experiments. The authors report that MOTS-c treatment was associated with improved blood perfusion, enhanced angiogenesis, and better collagen remodeling in ischemic flaps. Mechanistically, the study found that MOTS-c appeared to suppress phosphorylation of PLA2G4A (cytosolic phospholipase A2) via the MAPK1/ERK2–MAPK3/ERK1–NF-κB signaling cascade, thereby reducing lysosomal membrane permeabilization (LMP), decreasing endothelial pyroptosis, and enhancing autophagy. AAV-mediated PLA2G4A overexpression in vivo was used to confirm this pathway. Key limitations include the absence of human clinical data and the complexity of the multi-modal experimental design, which makes it difficult to isolate individual mechanistic contributions.
Autophagy · Jun 2026DOI ↗ 🧪 TrialInsufficient
Registered observational trial (active not recruiting). Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
ClinicalTrials.gov · Jun 2026View trial ↗ 🧪 TrialInsufficient
Registered observational trial (active not recruiting). Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
ClinicalTrials.gov · Jun 2026View trial ↗ Limited · human
This retrospective cohort study used the TriNetX Global Research Network to examine whether GLP-1 receptor agonist (GLP-1 RA) use was associated with a reduced risk of total knee arthroplasty (TKA) in adults with knee osteoarthritis (OA) diagnosed between 2010 and 2024. Patients exposed to GLP-1 RAs (either any agent or newer agents—semaglutide or tirzepatide) were propensity score matched to unexposed controls, balancing for age, sex, race, musculoskeletal diagnoses, obesity-related conditions, BMI, and healthcare access proxies. Matched cohort sizes ranged from approximately 13,000 to 42,000 patients depending on the exposure class and treatment duration analyzed (1 or 3 years). The primary outcome was cumulative TKA incidence at 1, 3, 5, and 8 years, estimated via Kaplan-Meier curves and Cox proportional hazards models. The study found that GLP-1 RA use was associated with significantly lower TKA incidence across all subgroups, with larger reductions observed with longer treatment durations and with newer-generation agents. The authors suggest the findings are consistent with possible disease-modifying activity beyond weight loss, but acknowledge that as a retrospective observational design, causality cannot be established, and prospective randomized trials are needed.
Regional anesthesia and pain medicine · Jun 2026DOI ↗ Animal only
This mouse study investigated whether adjunctive thymosin beta-4 (Tβ4) combined with the antibiotic ciprofloxacin could restore corneal nerve integrity and visual function following Pseudomonas aeruginosa bacterial keratitis, a serious eye infection. Researchers induced keratitis in C57BL/6 mice by inoculating wounded corneas with P. aeruginosa, then administered one of four topical treatments three times daily beginning 24 hours post-infection: PBS (vehicle control), Tβ4 alone, ciprofloxacin alone, or Tβ4 combined with ciprofloxacin. Outcomes assessed included clinical disease severity, visual acuity, contrast sensitivity, corneal sensitivity (nerve function), and corneal nerve density/architecture via β-III tubulin immunofluorescence. The study found that the combination of Tβ4 and ciprofloxacin outperformed all monotherapy and control groups across every measured outcome, restoring nerve density and visual function to levels comparable to uninfected controls. Key limitations include the exclusive use of an animal model, meaning findings may not directly translate to humans, and the study does not address long-term safety, optimal treatment windows, or clinical feasibility. These results suggest Tβ4 may be a promising adjunctive therapy warranting further investigation.
Investigative ophthalmology & visual science · Jun 2026DOI ↗ Limited · human
Two single-dose pharmacokinetic studies investigated whether renal or hepatic impairment affects how the body processes cagrilintide, a long-acting amylin agonist in development for weight management and type 2 diabetes (also studied in combination with semaglutide as "CagriSema"). In each study, adult participants were grouped by organ function (normal, mild, moderate, or severe impairment) and received a single subcutaneous dose of cagrilintide. The renal study enrolled 33 participants and the hepatic study enrolled 32. The primary measure was total drug exposure (AUC₀–∞), with secondary measures including peak concentration (Cmax) and time to peak (tmax). Both studies found that cagrilintide exposure was broadly similar across all impairment levels; estimated AUC ratios relative to normal function ranged from approximately 0.99 to 1.23, with overlapping confidence intervals. No serious adverse events, study withdrawals, or deaths occurred, and no increase in adverse events was observed with worsening organ impairment. The authors concluded that dose adjustment may not be necessary in these populations. Key limitations include small group sizes, single-dose design, and the inability to generalize to steady-state conditions or combined therapies.
Clinical pharmacokinetics · Jun 2026DOI ↗ Review
This paper is a commentary/review published in Cell Host & Microbe that discusses the expanding role of the gut microbiome in mediating the effects of glucagon-like peptide 1 (GLP-1) receptor agonists. The authors highlight findings from a study by Bian et al., which investigates how the gut microbiome may be involved in the psychological effects of GLP-1 receptor agonist drugs. The commentary contextualizes these findings within the broader landscape of GLP-1 pharmacology, noting that there is substantial evidence for the wide-ranging health benefits of GLP-1 receptor agonists. The paper underscores the concept of drug-microbe-host interactions, suggesting that the therapeutic and psychological effects of GLP-1 receptor agonists may not be solely attributable to direct drug action but may also involve modulation of the gut microbiome. Limitations include the nature of the article as a secondary commentary rather than primary research, meaning it does not present original experimental data. Its conclusions are largely interpretive, and the strength of any causal claims about the microbiome's role depends on the primary studies it references.
Cell host & microbe · Jun 2026DOI ↗ Insufficient
This News and Perspectives article, published in JMIR, examines the intersection of US policy changes and the growth of digital health platforms as factors influencing the affordability and accessibility of GLP-1 receptor agonist medications for obesity. The piece discusses how emerging access models—combining policy reform with telehealth and online pharmacy platforms—may expand patient access to these treatments, which have historically been cost-prohibitive for many individuals. As a journalistic and opinion-oriented piece rather than an original empirical study, it does not present primary data, clinical trial results, or systematic evidence. It instead contextualizes current trends and speculates on potential implications for the healthcare landscape. Key limitations include the absence of original research data, no patient outcomes measured, and an inherently perspective-driven framing. Readers should note that the article reflects one correspondent's analysis of a rapidly evolving policy and commercial environment, and conclusions about real-world impact on patient outcomes remain untested at this stage.
Journal of medical Internet research · Jun 2026DOI ↗ Limited · human
This qualitative study explored the lived experiences of 30 U.S. adults who were currently taking or had previously taken GLP-1 receptor agonists (GLP-1 RAs) for any indication, recruited via ResearchMatch and snowball sampling across 15 states. Semi-structured video interviews conducted in mid-2025 were analyzed using inductive thematic analysis. Researchers identified eight themes grouped under two domains. The first domain—patient-reported benefits and trade-offs—included reductions in "food noise," appetite, and psychological hunger; recognition that GLP-1 RAs are not standalone weight loss solutions; a wide spectrum of adverse effects; and willingness to tolerate significant side effects and logistical burdens to achieve weight loss goals. The second domain—social, clinical, and structural context—highlighted perceived stigma tied to prescription indication, highly variable clinical support and patient education, prohibitive costs and access barriers, and the value patients placed on shared peer experiences. The study concludes that participants viewed GLP-1 RAs as facilitators of, rather than replacements for, lifestyle change, and that inconsistent clinical support points to a need for standardized patient education guidelines. Key limitations include a small, non-random sample and potential self-selection bias inherent to qualitative recruitment methods.
JAMA network open · Jun 2026DOI ↗ Moderate · humanPreprint
This systematic review and meta-analysis, conducted following PRISMA 2020 guidelines, examined the effects of GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GIP/GLP-1 receptor agonist tirzepatide on obstructive sleep apnea (OSA) severity, as measured by apnea-hypopnea index (AHI). The authors searched PubMed, Google Scholar, and SciSpace through May 2026 and included 40 studies involving adults with OSA receiving GLP-1–based therapies with quantitative AHI outcomes. The review found that tirzepatide was associated with greater AHI reductions (−25.3 to −29.3 events/h; approximately 50.7%–58.7%) compared with liraglutide (−12.2 events/h; ~25%), and a pooled meta-analytic estimate showed an overall AHI reduction of −16.57 events/h across therapies. The authors attributed these effects primarily to weight loss, while noting emerging evidence for potential weight-independent mechanisms. Limitations include the heterogeneity of included studies, reliance on a preprint-stage document, and the inability to fully disentangle weight-mediated versus direct effects. The authors conclude that GLP-1–based therapies, particularly tirzepatide, may represent meaningful treatment options for obesity-related OSA, especially among patients with poor CPAP adherence.
Unknown journal · Jun 2026DOI ↗ Review
This commentary examines the Institute for Clinical and Economic Review (ICER) report on GLP-1 receptor agonists (GLP-1 RAs) — specifically semaglutide and tirzepatide — for obesity management, evaluating both their clinical value and the challenges surrounding their financing. The authors note that while these agents demonstrate meaningful weight loss and cardiometabolic benefits and were deemed cost-effective versus lifestyle modification alone by ICER, even modest real-world uptake surpasses ICER's annual budget impact threshold, raising access concerns. The commentary highlights that real-world persistence with these medications is notably lower than in clinical trials, leading to frequent weight regain upon discontinuation and limiting anticipated long-term medical cost offsets. Evidence on medical spending is described as mixed: cost-offset signals appear primarily in patients with both obesity and diabetes using high-potency injectable agents, while obesity-only populations may see spending increases. To address these tensions, the authors recommend pairing drug coverage with lifestyle management programs, avoiding arbitrary treatment duration limits, applying targeted prior authorization, and exploring innovative payment models. Key limitations include the commentary format, reliance on heterogeneous real-world data, and lack of primary data collection.
Journal of managed care & specialty pharmacy · Jun 2026DOI ↗ Insufficient
This scoping review, conducted following PRISMA-ScR guidelines, examines whether GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide, liraglutide, tirzepatide, and retatrutide — may interfere with autologous fat grafting outcomes. The authors note that millions of patients using GLP-1 RAs for weight loss now present to aesthetic surgeons with facial volume loss and soft tissue deflation, conditions commonly treated with fat grafting. The review synthesizes preclinical and clinical evidence on how GLP-1 RA medications affect adipocyte biology, adipose-derived stem cell (ASC) function, and tissue revascularization. The authors identify several theoretical interference points: GLP-1-mediated adipocyte "browning" and thermogenic activation (including UCP1 upregulation), enhanced lipolysis via ATGL and HSL pathways, suppression of white adipogenic differentiation in ASCs favoring beige/thermogenic lineages, and altered angiogenic and inflammatory signaling during the revascularization window critical to graft survival. The authors explicitly acknowledge that no clinical or preclinical studies have directly examined fat graft outcomes in patients receiving these therapies. The review's conclusions are framed as hypothesis-generating, and any clinical considerations offered are described as mechanism-based rather than evidence-based. This limits the paper's direct applicability to patient care.
Aesthetic surgery journal · Jun 2026DOI ↗